Tarsus Pharmaceuticals (TARS)
Commercializes XDEMVY for Demodex blepharitis and develops additional eye-care and infectious-disease therapies.
$75.97
vs last close−1.11 (−1.44%)
Something off on this page? Send us feedback.
Next report
Nov 3, 26
in 41 days
EPS estimate
−$1.43
Revenue estimate
$183.7M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.60−$0.64−$0.48−$0.30−$0.20−$0.16−$0.43Pending
Estimate−$0.68−$0.69−$0.33−$0.35−$0.10−$0.40−$0.19−$1.43
Surprise+11.8%+7.2%−45.5%+14.3%−94.2%+60.2%−124.2%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$66.4M$78.3M$102.7M$118.7M$151.7M$162.1M$173.9MPending
Estimate$64.5M$99.1M$113.0M$144.6M$144.6M$149.6M$169.7M$183.7M
Surprise+3.0%−21.0%−9.2%−17.9%+4.9%+8.3%+2.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $1.46 | — | — |
| Sep 2028 | $1.23 | — | — |
| Jun 2028 | $1.03 | — | — |
| Mar 2028 | $0.73 | — | — |
| Dec 2027 | $0.79 | — | — |
| Sep 2027 | $0.39 | — | — |
| Jun 2027 | $0.20 | — | — |
| Mar 2027 | −$0.22 | — | — |
| Dec 2026 | −$0.11 | — | — |
| Nov 2026 | −$1.43 | — | — |
| Aug 2026 | −$0.19 | −$0.43 | −124.2% |
| May 2026 | −$0.40 | −$0.16 | +60.2% |
| Feb 2026 | −$0.10 | −$0.20 | −94.2% |
| Nov 2025 | −$0.35 | −$0.30 | +14.3% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Oct 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2018 | |||
| Mar 2018 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $1.46 | — | — | $313.5M | — | — | — |
| Sep 2028 | $1.23 | — | — | $286.5M | — | — | — |
| Jun 2028 | $1.03 | — | — | $277.4M | — | — | — |
| Mar 2028 | $0.73 | — | — | $250.4M | — | — | — |
| Dec 2027 | $0.79 | — | — | $258.5M | — | — | — |
| Sep 2027 | $0.39 | — | — | $230.4M | — | — | — |
| Jun 2027 | $0.20 | — | — | $218.5M | — | — | — |
| Mar 2027 | −$0.22 | — | — | $192.9M | — | — | — |
| Dec 2026 | −$0.11 | — | — | $196.3M | — | — | — |
| Nov 3, 2026 | −$1.43 | — | — | $183.7M | — | — | — |
| Aug 6, 2026 | −$0.19 | −$0.43 | −124.2% | $169.7M | $173.9M | +2.5% | +6.6% |
| May 6, 2026 | −$0.40 | −$0.16 | +60.2% | $149.6M | $162.1M | +8.3% | −1.2% |
| Feb 23, 2026 | −$0.10 | −$0.20 | −94.2% | $144.6M | $151.7M | +4.9% | +7.8% |
| Nov 4, 2025 | −$0.35 | −$0.30 | +14.3% | $144.6M | $118.7M | −17.9% | −4.6% |
| Aug 6, 2025 | |||||||
| May 1, 2025 | |||||||
| Feb 25, 2025 | |||||||
| Nov 13, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 8, 2024 | |||||||
| Feb 27, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 9, 2023 | |||||||
| Mar 13, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 10, 2022 | |||||||
| Mar 14, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 4, 2021 | |||||||
| May 11, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Nov 25, 2020 | |||||||
| Oct 16, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 |